Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Google has rolled out major updates to its Gemini AI models, enhancing their speed, intelligence, and accessibility for ...

Formula E and Google Cloud have recently announced a new multi-year AI and technology partnership which kicked off with the groundbreaking GEN3 Evo era.

Google’s Najeeb Jarrar says that brands that prioritise mindful marketing and champion data privacy will be the ones that ...

The companies will combine Everseen's Vision AI platform with Google Distribute Cloud and Google's Vertex AI platform ... This year has also seen Google Cloud expanding its partnership with Formula E, ...

Keep your eye on the ball” is a motto for many athletes—and for astronomers trying to find Earth-threatening space rocks ...

It's back to European football this week, and battle to make the last 16 is heating up. Elsewhere, Ichiro Suzuki enters baseball hall of fame Liverpool beat Lille 2-1 on Tuesday to maintain their ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...